MedTrace Logo

[68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients

NCT05222269 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2025-09-05

No results posted yet for this study

Summary

This will be an open, single-arm, international, multicentre, phase II imaging study to assess the predictive value of \[68Ga\]Ga PentixaFor PET imaging in primary and isolated secondary central nervous system lymphoma (CNSL) patients scheduled to undergo induction chemotherapy.

Conditions

  • CNS Lymphoma

Interventions

DRUG

68Ga-PTF

68Ga-PTF will be injected intravenously at three time points during the course of the standard treatment of the patient.

Sponsors & Collaborators

  • Pentixapharm AG

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-05
Primary Completion
2023-01-25
Completion
2023-01-25

Countries

  • Denmark
  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05222269 on ClinicalTrials.gov